Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NUVB with free AI briefings, catalyst countdowns, and dilution alerts.

NUVB · Nuvation Bio Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$725.8M Cash on Hand
53.4mo Cash Runway
27.3% Short Interest
$13 Analyst Target (11)
Follow NUVB by email Get an email when NUVB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NUVB, unsubscribe in one click. Privacy

📣 What NUVB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Taletrectinib (AB-106)
FDA approved Jun 2025 · Ibtrozi
Non Small Cell Lung Cancer Phase 3 · NCT06564324 Recruiting
Safusidenib Glioma Phase 3 · NCT05303519 Recruiting
Drug-drug Conjugate NUV-1511 Advanced Solid Tumor Phase 1/2 · NCT06334432 Active not recruiting
Inixaciclib (NUV-422) Advanced Breast Cancer Phase 1/2 · NCT05191004 Withdrawn
BD2-selective BET Inhibitor NUV-868 Advanced Solid Tumor Phase 1 · NCT05252390 Terminated
Multiple administration of omeprazole Single… Pharmacokinetic Study Phase 1 · NCT05609929 Completed
Part A: Safusidenib Erbumine Glioma Early Phase 1 · NCT05577416 Completed
Part B: Safusidenib Erbumine Glioma Early Phase 1 · NCT05577416 Completed
Cancer treatment with tyrosine kinase… Cancer N/A · NCT04151342 Recruiting

Also used in these trials (approved or third-party drugs, not NUVB's own candidates): Crizotinib, Enzalutamide, Fulvestrant, Olaparib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NUVB holds $725.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $40.8M/quarter from operations, an estimated runway of 53.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NUVB files for a raise →

👥 Who Owns NUVB

Insiders 17% Institutions (334 holders) 72% Public and other holders 11%
HolderTypeShares% of sharesAs of
David Hung
PRESIDENT AND CEO, Director, 10% owner · +2.00M options
Insider 59,281,054 16.79% 2025-06-16
FMR, LLC Institution (13F) 52,230,295 14.80% 2026-06-30
Blackrock Inc. Institution (13F) 27,630,837 7.83% 2026-06-30
Decheng Capital LLC Institution (13F) 25,954,439 7.35% 2026-06-30
Vanguard Capital Management LLC Institution (13F) 11,919,514 3.38% 2026-06-30
Omega Fund Management, Llc Institution (13F) 8,081,089 2.29% 2026-06-30
Laurion Capital Management, LP Institution (13F) 7,820,013 2.22% 2026-06-30
State Street Corporation Institution (13F) 7,370,794 2.09% 2026-06-30
Geode Capital Management, LLC Institution (13F) 6,244,805 1.77% 2026-06-30
Duquesne Family Office Llc Institution (13F) 4,539,800 1.29% 2026-06-30
American Century Companies Inc Institution (13F) 4,499,643 1.27% 2026-06-30
Robert Mashal
Director · +864,576 options
Insider 225,000 0.06% 2026-06-09

Share count 353,017,638 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-19
filed 2026-08-21
Hattersley Gary
Sale (S) 100,000 $7.09 0
2026-08-19
filed 2026-08-21
Hattersley Gary
Option exercise (M) 100,000 $1.87 100,000
2026-08-19
filed 2026-08-21
Hattersley Gary
Option exercise (M) 100,000 – –
2026-07-15
filed 2026-07-17
Sauvage Philippe
Option exercise (M) 1 – –
2026-07-15
filed 2026-07-17
Sauvage Philippe
Option exercise (M) 39,999 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full NUVB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NUVB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.